Key result
Diminazene aceturate (DIZE) activates ACE2 and demonstrates beneficial effects in experimental models of cardiovascular disease, though clinical studies are unlikely due to its toxicity.
Population
Experimental models of cardiovascular disease
Design
Review
Authors
Loading...
Supports ACE2 activation via diminazene for CV protection; extends experimental data, warranting clinical trials.
Diminazene aceturate demonstrates the therapeutic potential of ACE2 activation in experimental cardiovascular models, though its toxicity necessitates the development of safer alternatives for clinical use.
Velkoska et al. (2016) conducted a review in Cardiovascular disease. Diminazene aceturate (DIZE) was evaluated. Diminazene aceturate (DIZE) activates ACE2 and demonstrates beneficial effects in experimental models of cardiovascular disease, though clinical studies are unlikely due to its toxicity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: